Drugs / NX-1607
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05107674 | Sep 2021 → Aug 2026 overdue | Richter transformation, castration-resistant prostate carcinoma, cervical cancer, colorectal carcinoma +10 | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Nurix Therapeutics, Inc. | Results Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 nurixtx.com ↗
In preclinical studies, NX-1607 enhanced T cell activation, as evidenced by increased IL-2 and IFN-γ secretion in response to TCR stimulation, and demonstrated single-agent anti-tumor activity across multiple syngeneic tumor models, including colorectal, triple-negative breast cancer, and B cell lymphoma. |
| 2024-11-19 | Ichnos Sciences SA | Results Corporate Presentation November 2024 Update iginnovate.com ↗
GRC 65327 Facilitates Robust Immune-Mediated Tumor Cell Killing |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | Nurix Therapeutics, Inc. | Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 nurixtx.com ↗ |
| 2024-11-19 | Ichnos Sciences SA | Corporate Presentation November 2024 Update iginnovate.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-1607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107674 ↗ |
| Action | Inhibit | “Cbl-b Inhibitor” NCT05107674 ↗ |
| Route | Oral | “Oral NX-1607” NCT05107674 ↗ |
| Target | CBLB | “Cbl-b Inhibitor” NCT05107674 ↗ |